Merck & Co posts strong 3rd-qtr 2011results as profit leaps 9.9% and sales rise 8%

31 October 2011

US drugs giant Merck & Co (NYSE: MRK) post third-quarter 2011 financial results late Friday, showing that, on a non-GAPP bases, net profit was $2.91 billion euros, or earnings per share of $0.94 a share, a rise of 9.9%, beating the Thomson Reuters consensus estimates of $0.91. On a GAPP basis net income rocketed nearly five-fold from $342 million, or $0.11 a share one year ago, to $1.69 billion, or $0.55 per share. Revenues were up 8% to $12.02 billion, also exceeding analysts’ forecasts of $11.6 billion.

The company has raised the lower end of 2011 non-GAAP EPS range of $3.72 to $3.76. It also revized its GAAP EPS range to $2.03 to $2.2 and expects full-year 2011 revenue growth in the mid single-digit range. Merck’s shares gained 2.3% to $35.11 in late trading on Friday.

Pharmaceutical sales performance

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical